H.R. 1266 House Crime and Law Enforcement
Combating Illicit Xylazine Act
House Floor, still liveSTAGE 4 OF 8 — HOUSE FLOOR
Currently in the House. Last action: received in the senate. read twice. placed on senate legislative calendar under general orders. calendar no. 623 on Sep 16, 2026.
- House Introduced in House Feb 12, 2025
- House Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. Feb 12, 2025
- House Referred to the Subcommittee on Health. Feb 12, 2025
- House Subcommittee Consideration and Mark-up Session Held Jun 25, 2026
- House Forwarded by Subcommittee to Full Committee by Voice Vote. Jun 25, 2026
- House Committee Consideration and Mark-up Session Held Jul 20, 2026
- House Committee Consideration and Mark-up Session Held Jul 21, 2026
- House Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 48 - 0. Jul 21, 2026
- House Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-816, Part I. Sep 14, 2026
- House Committee on the Judiciary discharged. Sep 14, 2026
- House Placed on the Union Calendar, Calendar No. 715. Sep 14, 2026
- House Considered under suspension of the rules. (consideration: CR H5671-5673) Sep 15, 2026
- House On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5671-5672) Sep 15, 2026
- House Mr. Guthrie moved to suspend the rules and pass the bill, as amended. Sep 15, 2026
- House Considered under suspension of the rules. Sep 15, 2026
- House DEBATE - The House proceeded with forty minutes of debate on H.R. 1266. Sep 15, 2026
- House Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. Sep 15, 2026
- House On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. Sep 15, 2026
- House Motion to reconsider laid on the table Agreed to without objection. Sep 15, 2026
- Senate Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 623. Sep 16, 2026
Cosponsors
114
Subjects
Congressional oversightConsumer affairsCriminal procedure and sentencingDrug safety, medical device, and laboratory regulationDrug trafficking and controlled substancesLicensing and registrationsManufacturingU.S. Sentencing CommissionVeterinary medicine and animal diseases
Committees
- Judiciary Committee
- [Discharged From, Sep 14, 2026]
- [Referred To, Feb 12, 2025]
- Energy and Commerce Committee
- [Reported By, Sep 14, 2026]
- [Markup By, Jul 21, 2026]
- [Markup By, Jul 20, 2026]
- [Referred To, Feb 12, 2025]
Summary
Combating Illicit Xylazine ActThis bill regulates xylazine under the Controlled Substances Act (CSA).Xylazine, also known as tranq, is a nonopioid sedative and pain reliever that is approved for use in animals. Recently, the Drug Enforcement Administration (DEA) has reported an increase in trafficking of fentanyl mixed with xylazine.This bill adds xylazine, including its salts, isomers, and salts of isomers, to schedule III of the CSA. Schedule III controlled substances, including anabolic steroids, buprenorphine, and ketamine, have less potential for abuse than a schedule I or II substance, have a currently accepted medical use, and have low or moderate risk of dependence if abused.Under the bill, manufacturing, distributing, or dispensing xylazine, or possessing with intent to manufacture, distribute, or dispense xylazine for illicit use is subject to criminal penalties under the CSA. The bill also requires xylazine transactions to be tracked in the drug reporting system maintained by the DEA.The bill exempts from registration under the CSA persons and entities that possess xylazine (1) lawfully dispensed by a veterinarian or pharmacy and (2) for an animal or for use in certain animal-control or wildlife programs.The bill also exempts xylazine manufacturers from the CSA's physical security requirements.Finally, the bill requires the DEA, in coordination with the Food and Drug Administration, to report on (1) the prevalence and impact of illicit xylazine use in the United States, and (2) updated information on the prevalence and proliferation of xylazine trafficking and misuse in the United States.
[Summary as of: Introduced in House]
Comments · 0
Please log in to post a comment.
Loading comments...